Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Stelexis Therapeutics LLC maintains a company patent portfolio focused within the Biotechnology & Pharmaceuticals technology area. This specific sector often involves complex regulatory and technical hurdles, yet the current portfolio shows a highly concentrated prosecution footprint. There is currently 1 pending office action across the entire portfolio, indicating a narrow window of active engagement with the patent office at this time.
The prosecution is handled by 1 distinct examiner working within 1 distinct art unit. This total concentration suggests that the company's current patenting efforts are focused on a singular technological niche or a very specific set of claims. KAUFMAN, CLAIRE M is identified as the busiest examiner for this portfolio. This individual is responsible for the 1 pending office action currently on record.
Having 1 distinct examiner manage the entirety of the pending work allows for a consistent dialogue between the applicant and the USPTO. Because the busiest examiner pending count is 1, the workload is not distributed but centralized. This structure means that the outcome of the current Biotechnology & Pharmaceuticals filings depends entirely on the interactions with this single official.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KAUFMAN, CLAIRE M | 1 | 63.3% | +50.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18019164 | IL-8 ANTIBODIES AND METHODS OF USE THEREOF | KAUFMAN, CLAIRE M | — |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18019164 | IL-8 ANTIBODIES AND METHODS OF USE THEREOF | KAUFMAN, CLAIRE M | 1674 | §112 | Non-Final OA | — | Pending | Feb 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialStelexis Therapeutics LLC has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Claire M Kaufman has the most, with 1 of Stelexis Therapeutics LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.